In:
International Journal of Cancer, Wiley, Vol. 134, No. 4 ( 2014-02), p. 988-996
Abstract:
What's new? The tyrosine kinase inhibitor imatinib has become the standard therapy for Chronic Myeloid Leukemia (CML). However, imatinib is not curative since most patients who discontinue therapy relapse, indicating that leukemia initiating cells are resistant. Here the authors demonstrated that arsenic and interferon alpha (IFN) inhibited the clonogenic activity of human primary CML cells. In a murine CML model, arsenic/IFN sharply diminished transplantation of CML cells, pointing to exhaustion of CML initiating cells. These studies plea for clinical exploration of this combination, knowing that IFN and arsenic have both previously shown clinical activity in CML, alone or in combination with imatinib.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink